Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary - Thomson StreetEvents

Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary

Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary - Thomson StreetEvents
Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary
Published Nov 02, 2023
17 pages (10332 words) — Published Nov 02, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Preliminary Brief of RARE.OQ earnings conference call or presentation 2-Nov-23 9:00pm GMT

  
Brief Excerpt:

...A. Interim data from the Phase II portion of the study demonstrated that setrusumab significantly reduced the analyzed fracture rate by 67% after at least 6 months of treatment and continue to demonstrate ongoing substantial increases in lumbar spine bone mineral density reaching 19% in just 6 months in the younger patients. B. The third program we highlight was our UX701 AAV gene therapy for Wilson disease. C. We provided data on the 5 patients in the first lowest dose cohort at [5e12GC] per kilo, 4 of the 5 patients showed improvements in copper trafficking and have begun tapering off standard of care with key layers and or zinc therapy. D. As of Q3 2023, there are over 460 patients on reimbursed therapy, which includes approximately 50 new patients who began from commercial therapy in this quarter. E. This year alone, we have converted approximately 150 new patients to the commercial drug in this region. F. The Latin America team has continued to build solid momentum, further strengthened...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Ultragenyx Pharmaceutical Inc
Ticker
RARE.OQ
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Carly Nicole Kenselaar - Citigroup Inc., Research Division - Analyst : This is Carly on for Yigal. We had one commercial question. It looks like you're expecting a pretty significant reacceleration in revenues in the fourth quarter in order to meet the guidance range. I know you mentioned an inventory impact to Crysvita during the third quarter. But can you talk a little bit more about your assumptions driving that acceleration in revenue that you're expecting?

Question: Carly Nicole Kenselaar - Citigroup Inc., Research Division - Analyst : Okay. Great. That's helpful. And then maybe just one follow-up related to the Wilson program. Can you just tell your thinking about the size of the addressable population for a gene therapy approaching Wilson? And maybe what you're hearing from KOLs about the proportion of patients not well managed on chelators and on the more severe end of the disease spectrum that could be addressable?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Can you provide any more color or thoughts around the timing of the interim analysis of the OI study?

Table Of Contents

Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting Summary – 2024-06-18 – US$ 54.00 – Edited Brief of RARE.OQ shareholder or annual meeting 18-Jun-24 4:30pm GMT

Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript – 2024-06-11 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 11-Jun-24 2:00pm GMT

Ultragenyx Pharmaceutical Inc at TD Cowen Health Care Conference Transcript – 2024-03-04 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 4-Mar-24 2:10pm GMT

Ultragenyx Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript – 2023-11-14 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 14-Nov-23 12:30pm GMT

Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Transcript – 2023-11-02 – US$ 54.00 – Edited Transcript of RARE.OQ earnings conference call or presentation 2-Nov-23 9:00pm GMT

Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Summary – 2023-10-16 – US$ 54.00 – Edited Brief of RARE.OQ corporate analyst meeting</ 16-Oct-23 12:30pm GMT

Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript – 2023-10-16 – US$ 54.00 – Edited Transcript of RARE.OQ corporate analyst meeting</ 16-Oct-23 12:30pm GMT

Ultragenyx Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 12-Sep-23 12:50pm GMT

Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Summary – 2023-09-06 – US$ 54.00 – Edited Brief of RARE.OQ presentation 6-Sep-23 12:50pm GMT

Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Transcript – 2023-09-06 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 6-Sep-23 12:50pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary" Nov 02, 2023. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2023-Ultragenyx-Pharmaceutical-Inc-Earnings-Call-B15784197>
  
APA:
Thomson StreetEvents. (2023). Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary Nov 02, 2023. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2023-Ultragenyx-Pharmaceutical-Inc-Earnings-Call-B15784197>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.